Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: A pilot study

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 2, 2011, Pages 514-523

  Gahramanov, Seymur ^a   Raslan, Ahmed M ^a   Muldoon, Leslie L ^a   Hamilton, Bronwyn E ^b   Rooney, William D ^a   Varallyay, Csanad G ^a,c   Njus, Jeffrey M ^a   Haluska, Marianne ^a   Neuwelt, Edward A ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Blood brain barrier; Dynamic susceptibility weighted contrast enhanced magnetic resonance imaging; Glioblastoma multiforme; Pseudoprogression; Radiochemotherapy

Indexed keywords

BLOOD-BRAIN BARRIER; DYNAMIC SUSCEPTIBILITY-WEIGHTED CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA MULTIFORME; PSEUDOPROGRESSION; RADIOCHEMOTHERAPY;

BLOOD; IRON OXIDES; LAKES; MAGNETIC SUSCEPTIBILITY; NANOMAGNETICS; RESONANCE; TUMORS;

MAGNETIC RESONANCE IMAGING;

FERUMOXYTOL; GADOTERIDOL; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DYNAMIC SUSCEPTIBILITY WEIGHTED CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; BLOOD VOLUME; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; YOUNG ADULT;

EID: 78650824830     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.10.072     Document Type: Article

References (31)

1. D. Brandsma, L. Stalpers, and W. Taal Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 2008 453 461
2. C. Chaskis, B. Neyns, and A. Michotte Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations Surg Neurol 72 2009 423 428
3. M.C. Chamberlain, M.J. Glantz, and L. Chalmers Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 2007 81 83
4. P.J. Tofilon, and J.R. Fike The radioresponse of the central nervous system: a dynamic process Radiat Res 153 2000 357 370
5. C.S. Wong, and A.J. Van der Kogel Mechanisms of radiation injury to the central nervous system: Implications for neuroprotection Mol Interv 4 2004 273 284
6. R.A. Nordal, A. Nagy, and M. Pintilie Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: A role for vascular endothelial growth factor Clin Cancer Res 10 2004 3342 3353
7. A.A. Brandes, A. Tosoni, and F. Spagnolli Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology Neuro Oncol 10 2008 361 367
8. A.A. Brandes, E. Franceschi, and A. Tosoni MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2008 2192 2197
9. H.J. Aronen, I.E. Gazit, and D.N. Louis Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings Radiology 191 1994 41 51
10. E.A. Knopp, S. Cha, and G. Johnson Glial neoplasms: Dynamic contrast-enhanced T2-weighted MR imaging Radiology 211 1999 791 798
11. T. Sugahara, Y. Korogi, and M. Kochi Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas AJR Am J Roentgenol 171 1998 1479 1486
12. M.H. Lev, Y. Ozsunar, and J.W. Henson Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: Confounding effect of elevated rCBV of oligodendrogliomas [corrected] AJNR Am J Neuroradiol 25 2004 214 221
13. Y. Cao, C.I. Tsien, and V. Nagesh Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected] Int J Radiat Oncol Biol Phys 64 2006 876 885
14. N. Danchaivijitr, A.D. Waldman, and D.J. Tozer Low-grade gliomas: Do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 247 2008 170 178
15. M. Law, R.J. Young, and J.S. Babb Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging Radiology 247 2008 490 498
16. J. Oh, R.G. Henry, and A. Pirzkall Survival analysis in patients with glioblastoma multiforme: Predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume J Magn Reson Imaging 19 2004 546 554
17. R.F. Barajas Jr., J.S. Chang, and M.R. Segal Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR Imaging Radiology 253 2009 486 496
18. F.W. Hoefnagels, F.J. Lagerwaard, and E. Sanchez Radiological progression of cerebral metastases after radiosurgery: Assessment of perfusion MRI for differentiating between necrosis and recurrence J Neurol 256 2009 878 887
19. L.S. Hu, L.C. Baxter, and K.A. Smith Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: Direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements AJNR Am J Neuroradiol 30 2009 552 558
20. A.G. Sorensen Perfusion MR imaging: Moving forward Radiology 249 2008 416 417
21. E.A. Neuwelt, C.G. Varallyay, and S. Manninger The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: A pilot study Neurosurgery 60 2007 601 611 discussion 611-602
22. C.G. Varallyay, L.L. Muldoon, and S. Gahramanov Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model J Cereb Blood Flow Metab 29 2009 853 860
23. Weinstein J, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and CNS inflammatory pathologies, a review. J Cereb Blood Flow Metab. epub ahead of print (16 September 2009).
24. M.W. Saif, A. Elfiky, and R.R. Salem Gastrointestinal perforation due to bevacizumab in colorectal cancer Ann Surg Oncol 14 2007 1860 1869
25. W. Rachinger, C. Goetz, and G. Popperl Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas Neurosurgery 57 2005 505 511
26. N. Tsuyuguchi, T. Takami, and I. Sunada Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery - in malignant glioma Ann Nucl Med 18 2004 291 296
27. Y. Cao, P.C. Sundgren, and C.I. Tsien Physiologic and metabolic magnetic resonance imaging in gliomas J Clin Oncol 24 2006 1228 1235
28. H.P. Schlemmer, P. Bachert, and K.K. Herfarth Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy AJNR Am J Neuroradiol 22 2001 1316 1324
29. H.P. Schlemmer, P. Bachert, and M. Henze Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy Neuroradiology 44 2002 216 222
30. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
31. E.S. Paulson, and K.M. Schmainda Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: Recommendations for measuring relative cerebral blood volume in brain tumors Radiology 249 2008 601 613